Tfelt-Hansen P
Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, DK-2600 Glostrup, Denmark.
Funct Neurol. 2000;15 Suppl 3:196-201.
In two, double-blind, randomised, clinical, trials (RCTs), oral lysine acetylsalicylate (1620 mg, equivalent to 900 mg aspirin) combined with metoclopramide (10 mg) (LAS + MTC) was compared with placebo, and with oral sumatriptan (100 mg) in one of these RCTs. In both RCTs the LAS + MTC combination was superior to placebo with therapeutic gains (percentage relief after active treatment minus percentage relief after placebo) of 30% and 31% for the first treated attack. These therapeutic gains are in the same range as those found for 100 mg oral sumatriptan, and in the comparative RCT the LAS + MTC combination was quite comparable to 100 mg sumatriptan, with success rates for the first attack of 57% and 53%, respectively.
在两项双盲、随机、临床试验（RCT）中，将口服赖氨酸乙酰水杨酸（1620毫克，相当于900毫克阿司匹林）联合甲氧氯普胺（10毫克）（LAS + MTC）与安慰剂进行比较，并且在其中一项RCT中将其与口服舒马曲坦（100毫克）进行比较。在两项RCT中，LAS + MTC组合均优于安慰剂，首次治疗发作的治疗获益（积极治疗后缓解百分比减去安慰剂后缓解百分比）分别为30%和31%。这些治疗获益与口服100毫克舒马曲坦的获益范围相同，并且在比较性RCT中，LAS + MTC组合与100毫克舒马曲坦相当，首次发作的成功率分别为57%和53%。
